Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis

Bradley Hall, James Padussis, Jason M. Foster

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)671-682
Number of pages12
JournalSurgical Clinics of North America
Volume97
Issue number3
DOIs
StatePublished - Jun 2017

Keywords

  • CC score
  • Cytoreductive surgery (CRS)
  • Hyperthermic intraperitoneal chemotherapy (HIPEC)
  • Intraperitoneal chemotherapy (IP)
  • Peritoneal carcinoma index (PCI)
  • Peritoneal metastasis (PM)
  • R score

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis'. Together they form a unique fingerprint.

  • Cite this